Sign In
Buy BBIO
$63.88
-1.48 (-2.26%)
At Close: Jun 02, 2026
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
11:15am, Sunday, 28'th Sep 2025
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 vers
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
07:30am, Monday, 22'nd Sep 2025
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 10'th Sep 2025
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma, Inc. (BBIO) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call (Transcript)
12:33pm, Wednesday, 10'th Sep 2025
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar Call Company Participants Ananth Sridhar Conference Call Participants Rachel Gafni Scott Adler Tyle
BridgeBio Pharma, Inc. (BBIO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
06:04pm, Monday, 08'th Sep 2025
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 3:20 PM EDT Company Participants Neil Kumar - Co-Founder, CEO & Director Presentation Un
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0%
BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
07:30am, Wednesday, 03'rd Sep 2025
PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism
07:30am, Tuesday, 02'nd Sep 2025
PALO ALTO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM
BridgeBio to Participate in September Investor Conferences
07:30am, Wednesday, 27'th Aug 2025
PALO ALTO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
07:30am, Monday, 25'th Aug 2025
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
‘BUY THAT THING': Historically undervalued stock now has value, says wealth expert
05:30pm, Tuesday, 19'th Aug 2025
Aquinas Wealth Advisors CEO Chris McMahon discusses the state of the economy, the success of healthcare stocks and more on ‘Making Money.' #foxbusiness #fox #usa #us #news #breakingnews #MakingMoney
BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript
04:30am, Saturday, 09'th Aug 2025
BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Ananth Sridhar - Chief Operating Officer Chinmay Shukla - VP IR & Strategic Financ
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates
06:26pm, Tuesday, 05'th Aug 2025
BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $1.02 per share a year ago.
BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates
04:01pm, Tuesday, 05'th Aug 2025
- As of August 1, 2025, 3,751 unique patient prescriptions have been written by 1,074 unique prescribers, representing an accelerating launch driven by strong month over month growth in the crucial tr
